New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival AdvantageSALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene ...
AKGsOVIHAMS, a leading healthcare institution, has marked progress in treating ALS using integrative medicine. Known for combining conventional and alternative therapies, the institute has shown ...
Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter ...
Columnist Dagmar Munn says she has often felt out of place in the ALS community because of the slower pace of her disease ...
Clene (CLNN) and its subsidiary, Clene Nanomedicine announced new evidence from a cross-regimen, post hoc analysis of long-term survival in ...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of eleven abstracts covering research in amyotrophic lateral sclerosis (ALS) at the 2025 Muscular Dystrophy Association ...
QRL-101-03 (NCT06532396) is a randomized, double-blind, placebo-controlled, multiple-ascending dose clinical trial evaluating the safety, tolerability, and PK of QRL-101 in up to 60 healthy ...
The Osaka High Court on Thursday upheld a lower court ruling that sentenced a former doctor to two years and six months in ...
Even the threat of cuts has had a chilling effect. The path that the administration is on will devastate STEM research in ...
VieMed, of a handful of publicly traded businesses in Lafayette, has reported double-digit increases in net revenue in each ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback